on chances of meaningful survival after discharge from myocardial ischemia, pulmonary embolism, diabetic intensive care with good quality of life. Patients with ketoacidosis, respiratory failure, sepsis cancer may need intensive care for varying reasons 5. Complications related to progression of disease, such as:
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Intensivists often refuse admission to cancer patients needing critical care, which may result in denial of effective care for some deserving patients. A cancer patient may need admission to intensive care units for a variety of reasons. The outcomes of patients with hematological malignancies, previously dismal, have improved over last 10 years. The previously known indicators of poor outcome are no longer valid in view of recent advances in intensive care. A select group of patients with hematological malignancies may be offered aggressive therapy for a limited duration and then prognosis can be reassessed.
Cancer chemotherapy can produce toxicities affecting all major organ systems. Such patients may be admit ted with acute organ dysfunction or years afterwards for incidental illnesses. Knowledge of these toxicities is essential for early diagnosis, management and prognostication in such patients.
The post-surgical cancer patient has unique problems, the problems of these groups are discussed. The post-surgical cancer patient may need care ranging from only monitoring; in view of supra-major surgery in some patients; to fully aggressive intensive care for post-surgical anastomotic dehiscence, mediastinitis, septic shock and multiorgan dysfunction in others. The metabolic and mechanical complications commonly seen in non-surgical cancer patients are also discussed. Intensive care should be offered to all cancer patients who have a reasonable chance of cure or palliation of their disease.
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Intensivists are often reluctant to offer critical care to 1. Postoperative care following major surgery cancer patients as a general rule, the main concern being 2. Treatment of complications after surgery, such as a potential waste of scarce resources. It is imperative to anastomotic dehiscence, peritonitis, mediastinitis, understand that such a policy may lead to a denial of hemorrhage effective care in some patients, as all cancer patients 3. Management of underlying medical comorbidity, such are not the same. The improving outcomes, particularly as chronic obstructive pulmonary diseases, ischemic in patients with hematological malignancies, means that heart disease the decision to provide intensive care should be based 4. Management of new medical conditions, e.g., patients, with febrile neutropenic sepsis being the commonest.
Intensive care in many of these categories is rewarding, with acceptable mortality and return to a reasonable quality of life in survivors. The prospect of survival of hematological malignancy patients admitted to intensive care was dismal. [1] [2] [3] [4] Recent articles, [5] [6] [7] [8] [9] [10] however report much lower mortality (50-60%) which, though high, is remarkably less than that reported 10 years ago. Some 3. Those in whom treatment has failed or no treatment is likely to be offered, except symptom control and palliative care.
In short, intensive care should be offered to all patients who have a reasonable chance of cure or palliation from their disease. The intensivist must be able to recognize the potentially reversible critical illness among the various groups of cancer patients and discourage admission to terminally sick cancer patients. The intensivist must also of the factors responsible for this improvement include be aware that the alleviation of the suffering in the last earlier referral to the ICU, earlier antibiotic therapy, better hours of the life a terminal cancer patient is also one of management of sepsis, hemodynamics and ventilation the functions of intensive care unit (ICU), once a decision and the use of non-invasive ventilation.
[11] However to discontinue aggressive therapy has been taken. neutropenia, septic shock and renal dysfunction are still poor prognostic factors and in such patients, mortality
Cancer patients presenting to the ICU are different still exceeds 80%. Thus with the possible exception of from the average patients in that they may have altered patients with severe, prolonged neutropenia with septic organ function by virtue of cancer itself, chemotherapy shock and respiratory and renal failure, many cancer or radiotherapy that they may have received or they may patients can be offered a reasonable chance of survival. have undergone a radical surgery. Over the past few years, Patients who have worsening organ failure scores after cancer treatment has become aggressive and is multithree days have a poor prognosis; [11] it is therefore a pronged, often involving aggressive chemotherapy and reasonable strategy to offer intensive care to patients with radiotherapy regimes to limit the extent of surgical resection hematological malignancies for three to four days and to to preserve limb or organ function (e.g., limb sparing reassess the prospects of survival at that stage.
surgery for osteogenic sarcoma, breast conservation surgery for carcinoma breast). Such regimes may induce A modification of the Australian classification [12] of toxic effects, some of which may require intensive care. patients with cancer, offers a reasonable starting point on Thus the distinction between a surgical patient and a deciding admission policies for patients with cancer:
'çhemotherapy' patient is becoming blurred. 1. Those undergoing diagnostic and other procedures to establish a diagnosis It is therefore necessary to know the toxicity of the 2. Those undergoing treatment which will result in cure various commonly used anti-neoplastic chemotherapeutic or significant control of disease that will prolong life agents and how it affects the various systems. Table 1 lists the toxicity of common chemotherapeutic agents. Effects of chemotherapeutic agents on the cardiorepsiratory system are of particular importance to the Intensivist and will be discussed in detail here. Effects on other organ systems will be briefl y discussed.
Cardiovascular Complications of Chemotherapy
Anthracyclines, i.e., doxorubicin (adriamycin), cancer chemotherapy. [13, 14] Cardiac toxicity can manifest due to fluid retention (docetaxel) at various times during and following the course of chemotherapy. Three types, depending on their appearance in relation to timing of therapy, have been identified.
Acute and subacute cardiotoxicity can occur immediately after a single dose or a course of anthracycline therapy. A variety of arrhythmias, including sinus tachycardia, ventricular, supraventricular and junctional tachycardia, atrioventricular and bundle-branch block have also been produced by bleomycin have been described: seen. Sudden death may also occur, due to ventricular 1. Dose dependant interstitial pneumonitis progressing fibrillation. Rare cases of subacute cardiotoxicity to chronic fibrosis resulting in acute failure of the left ventricle, pericarditis 2. An acute hypersensitivity pneumonitis with peripheral or a fatal pericarditis-myocarditis syndrome, particularly eosinophilia resembling eosinophilic pneumonia in children, have been reported. Chronic or late 3. An acute chest pain syndrome cardiotoxicity after anthracycline classically takes the form 4. A bronchitis obliterans with organizing pneumonia of cardiomyopathy. Patients who have survived cancer 5. Pulmonary veno-occlusive disease in childhood may come several years later with cardiac failure or cardiac failure may be precipitated during a
The earliest detection of pulmonary fibrosis may be surgical or other procedure undertaken years after the achieved through the serial evaluation of pulmonary primary cancer has been treated. Classic anthracycline function. Sequential measurement of carbon monoxide cardiotoxicity is a cumulative dose-related phenomenon. diffusion capacity (DLCO) may indicate the presence
Pulmonary Complications of Chemotherapy
Administration of several chemotherapeutic agents, such as busulfan, cyclophosphamide, paclitaxel, etc., can lead to pulmonary complications. Bleomycin, an antitumour antibiotic, is the foremost of these in producing lung damage. [15] [16] [17] [18] [19] Several patterns of pulmonary toxicity
The rapid increase in incidence of congestive cardiac of occult pulmonary changes. Arterial hypoxemia is failure (CCF) after a dose of 550 mg/m 2 has made it a commonly found and spirometry reveals decreased popular empiric-limiting dose for doxorubicin-induced cardiotoxicity. Occult ventricular dysfunction, heart failure and arrhythmias may occur in previously asymptomatic patients more than a year after anthracycline therapy. It is postulated that doxorubicin can cause subclinical myocardial injury during pre-adolescent years and this in later years retards appropriate growth of the myocardium during growth spurt.
Cardiovascular toxicity associated with othyer agents is summarized in Table 2 . lung volumes compatible with restrictive lung disease. Regression or amelioration of the toxic pulmonary pathology may occur with immediate cessation of therapy. Steroid therapy has been found to be effective in some cases.
Hyperoxia and bleomycin
Of utmost importance is the debate about the amount of oxygen to be administered to a patient given bleomycin. On the basis of available data, it seems prudent to reduce the concentration of inspired oxygen to the lowest level to maintain SpO 2 > 90%. The judicious use of PEEP to enhance oxygenation and the postoperative use of rigorous physiotherapy to treat ventilation-perfusion abnormalities may be preferable to the use of enriched oxygen concentrations. Conservative fl uid management is important; use of colloids is beneficial as compared to crystalloid. Other chemotherapeutic agents producing pulmonary toxicity are listed in Table 3 .
Effects of Chemotherapeutic Agents on The Post-Surgical Cancer Patient
Spectrum of postoperative care in cancer patients may range from patients following major surgery requiring intensive monitoring, nursing care and short term ventilatory support, to critically-ill patients with sepsis and multi-organ failure.
The general postoperative management after major surgery follows the routine course of care including the recovery from the residual action of anesthetic Renal, Hepatic and Central Nervous drugs, management of postoperative bleeding if any, Systems fluid balance, postoperative nutrition, pain relief and Cisplatinum, a commonly used platinum compound, was other surgery related issues. Several groups of cancer introduced in 1970s. The dose-limiting factor for single surgeries need special mention. agent use, however, is nephrotoxicity. [20, 21] 30% of patients receiving cisplatinum will develop nephrotoxicity, especially Head, neck, face and craniofacial cancer surgery if the hydration is not ensured. Cisplatinum leads to wasting Close to 40% of cancers in India originate in the head/ of magnesium and potassium. The renal toxicity may neck and face regions. Anticipated problems include a be accentuated if the patient receives aminoglycosides difficult airway due to trismus, major maxillofacial excision concomitantly. The newer analogues of cisplatinum, such and replacement of excised tissue by flaps, which make as carboplatin and oxaloplatin are less nephrotoxic with visualization of the airway impossible. These patients will equal efficacy in controlling the malignancy.
often need to have the tracheal tube in situ overnight to maintain the airway and to protect the airway from blood, Hepatocellular dysfunction is manifest as raised saliva and secretions, which the patient may not be able to serum enzymes, fatty infiltration of liver and cholestasis, swallow. It is not uncommon to have intraoral hemorrhage due to direct toxic effect of the drug or its metabolite. in first 12h after operation. The patient can choke on L-asparginase and cytarabine are most commonly his own blood if the airway is not protected. Usually, a implicated agents in hepatocellular dysfunction. A tracheostomy is electively performed in patients who decreased synthetic function with low proteins and undergo total glossectomy or undergo extensive excision coagulation abnormalities may be seen. Blockage of with mandibulectomy crossing the midline. the venous outflow in the small hepatic veins results in veno-occlusive disease. It can present abruptly and Prolonged intubation may lead to problems such as may have a fulminant course resulting in death. Ascites, blocked tubes, usually due to encrustation with blood painful hepatomegaly and encephalopathy may result clots and inadequate humidification, and unplanned after administration of cytarabine, cyclophosphamide, extubation. Removal of such an airway may lead to problems and reintubation may be difficult for the reasons mentioned earlier. Aspiration is a common reason for respiratory failure and readmission of patients to the ICU after Head and Neck surgery.
Esophageal surgery
Esophagectomy represents the highest risk among elective surgical procedures on any region.
A great deal of Indian population with cancer esophagus report late in the hospital and are already cachexic, dehydrated and chronically vasoconstricted due to prolonged hypovolemia. They require large amounts of fluids to compensate for the huge amount lost to third space. Mediastinal lymphadenectomy as a part of radical clearance interrupts many lymphatic channels; this leads to impaired removal of interstitial water. It is, therefore, mandatory to manage fl uid administration very carefully. A fine balance must be achieved so that interstitial edema is prevented but not at the cost of vital organ perfusion. In the absence of monitoring transplant or after intense chemotherapy producing agranulocytosis. The type of infection and organism producing infection will depend on the part of the immune system that is affected. For example after radical chemotherapy mucosal and skin barriers are breached and bacteria and candida will be the most likely pathogens. In the initial period of neutropenia following two to four weeks of transplant, herpes simplex virus, candida, aspergillus and bacterial infections predominate. of DO2, CI and VO2, adequacy of tissue perfusion The full chemotactic function of the neutrophil does is determined by monitoring base line CVS and RS not recover for 100 days post-transplant. From three parameters by correlation with CVP. The end point of the months to one year after transplant T cells and B cells values of these parameters is determined by correlating are dysfunctional and varicella-zoster, hepatitis C, with adequacy of urine output, absence of metabolic pneumocystis carinii pneumonia and pnuemococcal acidosis, normal bicarbonates, base deficit less than 3 pneumonia are the most common infections till T cell meq. and low serum lactate. Respiratory complications function recovers. The antibiotic prescription must take after esophagectomy are the result of interaction of into account these issues, and the local pathogenic flora. several factors viz., increase in the lung water (interstitial Management of immunocompromised patient is beyond edema), hypoventilation due to thoracotomy pain, the scope of this review. peripheral alveolar collapse, occasional sympathetic pleural effusion, dilated stomach tube acting as a space 2. Metabolic complications of cancer or cancer occupying lesion in the mediastinum, occult tracheo-chemotherapy [23] esophageal fistula silently soiling the mediastinum A wide variety of abnormalities occur such as and aspiration. Early enteral feeding via jejunostomy hypercalcemia or hyperphospatemia or Cushing's placed at surgery is the norm. Mediastinitis is a serious syndrome seen with small cell carcinoma of lung. A brief consequence of the leak at anastomotic site or along discussion of common disorders follows. the stomach tube. It is clinically suspected when the patient begins to have tachycardia or supraventricular a) Tumor lysis syndrome arrhythmia, bronchospasm, tachypnoea, respiratory Case reports of metabolic and electrolyte abnormalities failure and pleural effusion. The diagnosis of leak may in patient receiving chemotherapy for rapidly proliferating be confirmed by radiological technique after injection of tumours such as Burkitt's lymphoma and leukemias, were radio-opaque dye, CT scan or by visualization of ischemic first published in 1950s and later Bertino and colleagues or dehisced areas on esophagogastroscopy. The proposed the mechanism linking these observations. analysis of the drain fluid for amylase shows almost two The syndrome has also been described in chronic to four times higher values than normal. Disconnection of myeloid leukemia in an acute blast crisis, non-Hodgkin's the anastomosis with esophagostomy and gastrostomy lymphoma and occasionally in small cell cancer of the or drainage and thorough irrigation of the thoracic cavity lung and metastatic breast cancer. The syndrome is are the surgical options. Complications include sepsis, SIRS and progression to multiorgan dysfunction.
The Non-Surgical Cancer Patient in ICU
A cancer patient may require intensive care for several reasons: 1. Overwhelming infection and sepsis [22] These can occur in the setting of immunosupression seen following myeloablative therapy for bone marrow caused by rapid lysis of malignant cells resulting in hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia and an increase in blood urea nitrogen. These abnormalities can occur as early as six hours following chemotherapy and in the last five to seven days after treatment. The hyperuricemia is caused by the massive release of intracellular nucleic acids and their metabolism by xanthine oxidase into uric acid. Urate crystals can form in the renal collecting ducts and result into acute renal failure. Similarly, potassium and phosphate are released from the tumour cells and their excretion is hampered by the hyperuricemia. The best approach to management is to prevent its occurrence by proper hydration. Patient with diagnosis of rapidly growing lymphoma, uric acid levels of more than 10 mg/dl and high blast count in leukemia, high lactate dehydrogenase before treatment are at greatest risk of developing tumour lysis syndrome.
destruction of adrenals makes the patient symptomatic causing weakness, postural hypotension, electrolyte disturbances etc. Diagnosis is made with cosyntropin stimulation test. If the response is suboptimal physiologic doses of glucocorticoids need to be administered.
Many other metabolic and endocrine complications such oncogenic osteomalacia, tumor induced hypoglycaemia, etc., may occur. The complete description is beyond the scope of this discussion. Management of tumour lysis syndrome 1. Allopurinol 500 mg/m 2 /day for three days; this 3. Mechanical complications and complications due is reduced to 200 mg/m 2 /day after three days of to direct invasion of contiguous tissues chemotherapy. 2. Hydration 3000 ml/m 2 /day a) Cardiac complications 3. Urinary alkalinization (pH > 7) with NaHCO 3 100 ml/L Cardiac dysfunction in cancer patients can result from then adjust as needed mechanical effect of the tumors on the heart, pericardium 4. Replace calcium IV slowly and great vessels. Cardiac tamponade can occur due to 5. Monitor serum chemistry 12-24 hrs. In case of rise metastases from breast cancer, lung cancer, melanoma of uric acid postpone chemotherapy till levels are or leukemias. Encasement of the heart or malignant pericardial effusion leads to tamponade causing 6. Treat hyperkalemia with exchange resins shortness of breath, decreased exercise tolerance and 7. Aluminium hydroxide 30-60 ml six hourly is orally to cough. Urgent pericardiocentesis may be needed in bind phosphates the presence of hemodynamic compromise. Repeated 8. Hemodialysis if Sr K > 6 meq/L, Sr Uric acid > 10 filling of effusion may necessitate repeated drainage or mg/dL, Sr phosphorus rapidly rising or > 10 mg/dL. a pericardial window to be made surgically.
b) Hypercalcemia
Superior vena cava syndrome occurs due to obstruction Hypercalcemia is the commonest metabolic complication to the blood flow caused by mediastinal tumors, fibrosis, of malignancies. Approximately 10-2 0% cancer patients thrombosis and direct invasion of great vessels with will have hypercalcemia some time in course of their tumor. Facial and upper extremity edema, facial plethora malignancy. It is most frequently associated with multiple and tachypnoea are most common clinical presentations. myeloma, lung cancer, breast cancer, cancer involving Death can occur from respiratory compromise due to the head and neck, T-cell lymphomas, renal carcinoma, obstruction. The treatment depends on the underlying as well as other solid tumors. The clinical symptoms malignancy and hence a definitive tissue diagnosis are nonspecific and include lethargy, confusion, is essential. Lymphoma or small cell carcinoma may nausea and anorexia. In lymphomas and leukemias respond to chemotherapy and will reduce obstruction. In there is overproduction of activated vitamin D leading chemotherapy resistant tumors, radiotherapy may provide controlled to hypercalcemia. Vigorous hydration with intravenous normal saline combined with the use of furosemide, is the standard therapy. Corticosteroids, diphosphonates, mithramycin and calcitonin can all reduce serum calcium levels by reducing bone resorption of calcium.
d) Adrenal failure
Cancers of lung, breast, kidney, stomach and pancreas often metastasize to the adrenals. A more than 90% relief in significant number of patients.
b) Pulmonary complications
Mediastinal tumors, tumors causing SVC syndrome can cause mechanically induced respiratory compromise needing ventilatory assistance. Sometimes thymic tumors can act doubly by producing myasthenia as well as direct tracheal compression. Excision of tumor in such patients if possible can alleviate the respiratory compromise by both removal of obstruction and curing myasthenia in up to 40% patients. Direct lymphangitic spread of the tumor subsequently leads to pulmonary hypertension and cor pulmonale. The prognosis of this condition is very poor. A blanket refusal to provide intensive care to cancer 8. Kress JP, Christenson J, Pohlman AS, Linkin DR, Hall JB. Out patient is inadvisable. The decision to provide or deny comes of critically ill cancer patients in a university hospital setting.
care should be based not only on prognosis of the acute Am J Respir Crit Care Med 1999; 160:1957-61. illness but also the comorbidities, the availability of life prolonging treatment options and estimated chance of the patient having a reasonable survival with good quality of life. Some patients may be admitted to provide palliative care to alleviate suffering. The cancer patients may be admitted for a variety of reasons. Some postsurgical cancer patients present with unique problems related to presence of cancer and the intensivist needs to familiarise himself with these. The outcome for these patients is generally equivalent to the other non-cancer 
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